Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS)Breast Cancer
Interventions
DIAGNOSTIC_TEST

Initial blood draw

At baseline, patients will undergo a blood draw.

DIAGNOSTIC_TEST

Initial SWE ultrasound

At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.

DIAGNOSTIC_TEST

Blood draw at three months

Blood drawn at three months to evaluate oxylipins.

DIAGNOSTIC_TEST

Blood draw at six months

Blood drawn at six months to evaluate oxylipins.

DIAGNOSTIC_TEST

SWE ultrasound at six months

SWE ultrasound at six months to evaluate tendon stiffness.

Trial Locations (1)

85724

University of Arizona Cancer Center, Tucson

All Listed Sponsors
lead

University of Arizona

OTHER

NCT03665077 - Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome | Biotech Hunter | Biotech Hunter